Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in advanced malignancies
NCT02383212Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label trial of cemiplimab in solid tumor (advanced stage) and cutaneous squamous cell carcinoma (cSCC) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events at 48 weeks, Incidence of abnormal laboratory findings at 48 weeks and 1 more. Started Feb 2015; status: completed.
02
Drugs
cemiplimab
03
Conditions
solid tumor (advanced stage)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT02383212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383212.